Gi Tolerability

Rates of Treatment-Emergent Gastrointestinal Disorders Over 48 Weeks1

Chart 1
Chart 2

Please see full description of study design and baseline characteristics.

*Patients may have reported more than one gastrointestinal adverse drug reaction.

The BR for INTELENCE® and placebo arms consisted of darunavir/ritonavir ± ≥2 other investigator-selected ARVs (N[t]RTIs ± ENF). In the INTELENCE® arm (n=599), 25.5% of patients used ENF de novo and 20.0% reused ENF. In the placebo arm (n=604), 26.5% of patients used ENF de novo and 20.4% reused ENF.

Important Safety Information